What’s Propelling Veracyte Inc (NASDAQ:VCYT) After Lower Shorts Reported?

March 14, 2018 - By Hazel Jackson

 What’s Propelling Veracyte Inc (NASDAQ:VCYT) After Lower Shorts Reported?

Investors sentiment decreased to 1.76 in Q3 2017. Its down 0.12, from 1.88 in 2017Q2. It worsened, as 11 investors sold Veracyte, Inc. shares while 14 reduced holdings. 14 funds opened positions while 30 raised stakes. 22.46 million shares or 6.26% more from 21.14 million shares in 2017Q2 were reported.
Birchview Capital Ltd Partnership holds 118,767 shares or 0.54% of its portfolio. Manufacturers Life Insurance The reported 21,898 shares. Federated Invsts Pa has 0.01% invested in Veracyte, Inc. (NASDAQ:VCYT) for 525,000 shares. 11,502 were reported by Fincl Bank Of America De. Moreover, Credit Suisse Ag has 0% invested in Veracyte, Inc. (NASDAQ:VCYT) for 16,015 shares. Schwab Charles Inv Mgmt invested in 0% or 162,562 shares. Ny State Common Retirement Fund holds 0% or 25,200 shares in its portfolio. 12,937 are owned by Royal Savings Bank Of Canada. Voya Investment Mngmt Limited Company has 11,713 shares for 0% of their portfolio. Legal And General Grp Inc Public Limited accumulated 0% or 3,460 shares. American Inc holds 0% of its portfolio in Veracyte, Inc. (NASDAQ:VCYT) for 15,879 shares. Grandeur Peak Global Advsr Limited Co holds 328,039 shares or 0.44% of its portfolio. 11,336 are owned by Invesco Ltd. Deutsche Bankshares Ag invested in 108,728 shares or 0% of the stock. Ameritas Invest Prtn reported 1,394 shares.

Since September 25, 2017, it had 0 insider buys, and 3 sales for $381,180 activity. Hall Christopher M had sold 20,000 shares worth $180,000.

The stock of Veracyte Inc (NASDAQ:VCYT) registered a decrease of 0.67% in short interest. VCYT’s total short interest was 737,500 shares in March as published by FINRA. Its down 0.67% from 742,500 shares, reported previously. With 131,400 shares average volume, it will take short sellers 6 days to cover their VCYT’s short positions. The short interest to Veracyte Inc’s float is 3.54%.

The stock decreased 2.35% or $0.15 during the last trading session, reaching $6.24. About 71,260 shares traded. Veracyte, Inc. (NASDAQ:VCYT) has risen 56.46% since March 14, 2017 and is uptrending. It has outperformed by 39.76% the S&P500.

Veracyte, Inc. operates as a molecular diagnostics firm in the United States. The company has market cap of $213.98 million. The firm uses genomic technology to resolve diagnostic ambiguity. It currently has negative earnings. It offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers to manage thyroid nodule patients.

Veracyte, Inc. (NASDAQ:VCYT) Ratings Coverage

Among 6 analysts covering Veracyte (NASDAQ:VCYT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Veracyte had 11 analyst reports since August 14, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 14 by BTIG Research. The company was maintained on Friday, August 14 by Piper Jaffray. As per Tuesday, November 7, the company rating was downgraded by Piper Jaffray. Janney Capital downgraded the stock to “Neutral” rating in Tuesday, November 7 report. As per Tuesday, November 29, the company rating was upgraded by Janney Capital. Leerink Swann maintained it with “Outperform” rating and $9 target in Tuesday, November 7 report. Cantor Fitzgerald initiated it with “Buy” rating and $13.0 target in Friday, December 18 report.

More news for Veracyte, Inc. (NASDAQ:VCYT) were recently published by: Streetinsider.com, which released: “Form 4 VERACYTE, INC. For: Mar 02 Filed by: Hall Christopher M” on March 06, 2018. Businesswire.com‘s article titled: “Veracyte Announces New Data Demonstrating “Real-World” Performance of Afirma …” and published on March 14, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: